Basem M Alraddadi
Overview
Explore the profile of Basem M Alraddadi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
869
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alraddadi B, Heaphy E, Alzahrani M, Alqadi M, Qashqari M, Alhuthali M, et al.
Infect Drug Resist
. 2024 Oct;
17:4655-4664.
PMID: 39473910
Purpose: The study aimed to determine the impact of Carbapenem-resistant Enterobacterales (CRE) colonization status on development of CRE infection and 30-day mortality outcomes in high-risk patients. Patients And Methods: This...
2.
Batawi S, Alraddadi B
Lancet Infect Dis
. 2024 Oct;
25(2):146-148.
PMID: 39389072
No abstract available.
3.
Abdalla J, Albarrak M, Alhasawi A, Al-Musawi T, Alraddadi B, Al Wali W, et al.
Infect Dis Ther
. 2023 Jun;
12(7):1741-1773.
PMID: 37389707
Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) are the most common healthcare-associated infections, with rates varying between countries. Antimicrobial resistance (AMR) among common HAP/VAP pathogens has been reported, and multidrug...
4.
Alshukairi A, Aldabbagh Y, Adroub S, Mourier T, Abumelha K, Albishi G, et al.
J Epidemiol Glob Health
. 2023 Jan;
13(1):47-54.
PMID: 36626091
The outcome of transplant recipients is variable depending on the study population, vaccination status and COVID-19 variants. Our aim was to study the impact of Omicron subvariants on the mortality...
5.
Alraddadi B, Heaphy E, Aljishi Y, Ahmed W, Eljaaly K, Al-Turkistani H, et al.
BMC Infect Dis
. 2022 Jun;
22(1):542.
PMID: 35698046
Background: The burden of carbapenem resistance is not well studied in the Middle East. We aimed to describe the molecular epidemiology and outcome of carbapenem-resistant Enterobacterales (CRE) infections from several...
6.
Alhamlan F, Almaghrabi R, DeVol E, Alotaibi A, Alageel S, Obeid D, et al.
Medicines (Basel)
. 2022 May;
9(5).
PMID: 35622071
This study provides epidemiologic and clinical characteristics of 492 consecutive patients diagnosed with SARS-CoV-2 infection at King Faisal Specialist Hospital and Research Centre in Saudi Arabia between March and September...
7.
Almangour T, Aljabri A, Al Musawa M, Almohaizeie A, Almuhisen S, Damfu N, et al.
J Glob Antimicrob Resist
. 2022 Feb;
28:288-294.
PMID: 35121161
Objectives: The aim of this study was to compare the safety and effectiveness of ceftolozane-tazobactam (C-T) to colistin-based regimen for treating infections caused by multidrug-resistant (MDR) Pseudomonas aeruginosa. Methods: This...
8.
Alshukairi A, Doar H, Al-Sagheir A, Bahasan M, Sultan A, Al Hroub M, et al.
Front Endocrinol (Lausanne)
. 2022 Jan;
12:800376.
PMID: 35095767
Background: Although genetic diseases are rare, children with such conditions who get infected with COVID-19 tend to have a severe illness requiring hospitalization. Osteogenesis imperfecta (OI) is a rare genetic...
9.
Yamani A, Alraddadi B, Almaghrabi R, Amer A, Mehdawi F, Al-Hamzi M, et al.
Immun Inflamm Dis
. 2022 Jan;
10(3):e587.
PMID: 35029324
Background: Tocilizumab was studied to reduce cytokine syndrome in patients with severe COVID-19 pneumonia in solid organ transplant (SOT) recipients with conflicting results. We aim to study the early use...
10.
Alraddadi B, Saeedi M, Qutub M, Alshukairi A, Hassanien A, Wali G
BMC Infect Dis
. 2019 Sep;
19(1):772.
PMID: 31484510
Background: Carbapenem-resistant Enterobacteriaceae (CRE) represent an important global threat. The aim of this study is to describe the clinical course and outcomes of patients with CRE infections treated with ceftazidime-avibactam...